Pharma Giant Johnson & Johnson, Lupin Offer Significant Price Cuts On Tuberculosis Drug
Portfolio Pulse from Vandana Singh
Johnson & Johnson (JNJ) and Lupin Limited have announced significant price reductions for their tuberculosis drug, bedaquiline, to combat the disease in low- and middle-income countries. J&J's price has been reduced by 55% to $130, while Lupin's price has dropped by 33% to $194 for a six-month treatment course. The price reduction is expected to increase access to the drug, which is crucial in treating drug-resistant TB strains.
August 30, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson has reduced the price of its tuberculosis drug, bedaquiline, by 55% to $130 for a six-month treatment course. This move is expected to increase access to the drug in low- and middle-income countries.
While the price reduction of bedaquiline will likely increase access to the drug in low- and middle-income countries, it's unclear how this will impact J&J's revenues and profitability in the short term. The company's shares are currently up 0.41%.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100